In cancer cells, the inhibition of Hsp90 promotes the degradation of client oncoproteins, thereby making it a significant cancer therapeutic strategy (Bhat et al., 2014; Ozgur and Tutar, 2016; Liu et al., 2019). Here, HSP90AA1 is linked to cancer.